Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780102 | 0.89 | CA12 (0.39) | TMEM97KDM4EALDH1A1SMN1; SMN2ROCK2 | |
| SCHEMBL3116575 | 0.82 | ALDH1A1 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL3122259 | 0.79 | TMEM97 (0.48) | TMEM97MAPTALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13016805 | 0.79 | TMEM97 (0.48) | TMEM97MAPTALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3104786 | 0.78 | TMEM97 (0.39) | TMEM97MAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL13016818 | 0.78 | TMEM97 (0.39) | TMEM97MAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL3119879 | 0.74 | TMEM97 (0.40) | TMEM97MAPTMRGPRX4KDM4EALDH1A1 | |
| SCHEMBL3109578 | 0.72 | EGLN2 (0.40) | TMEM97ALDH1A1RAB9AFFAR1 | |
| SCHEMBL13016821 | 0.72 | EGLN2 (0.40) | TMEM97ALDH1A1RAB9AFFAR1 | |
| SCHEMBL3264797 | 0.72 | CA12 (0.40) | TMEM97MAPTKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | claimed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | claimed |
| US-20060270608-A1 | Drugs for chronic pain | NICOX S.A. (FR) | 2006-11-30 | — | — | US | claimed |
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7642289-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-01-05 | — | — | US | disclosed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | disclosed |
| US-20060270608-A1 | Drugs for chronic pain | NICOX S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | OPRK1, OPRL1, OPRD1 | TMEM97 555/4885MAPT 3760/4885MRGPRX4 852/4885 |
| US-20060270608-A1 | Drugs for chronic pain | OPRK1, OPRL1, OPRD1 | TMEM97 555/4885MAPT 3760/4885MRGPRX4 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.